Knight Therapeutics (TSE:GUD) Price Target Increased to C$5.40 by Analysts at Stifel Nicolaus

Knight Therapeutics (TSE:GUD) had its price target raised by Stifel Nicolaus from C$5.25 to C$5.40 in a research note published on Wednesday morning, BayStreet.CA reports. Stifel Nicolaus currently has a hold rating on the stock.

Other equities analysts have also issued research reports about the company. Royal Bank of Canada raised their price target on Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an outperform rating in a report on Friday, March 22nd. Raymond James raised their price target on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an outperform rating in a report on Wednesday, March 6th.

Knight Therapeutics Stock Performance

Shares of GUD stock opened at C$5.77 on Wednesday. The stock’s 50-day moving average is C$5.51 and its two-hundred day moving average is C$5.32. The firm has a market cap of C$583.75 million, a price-to-earnings ratio of -36.06, a PEG ratio of -1,013.50 and a beta of 0.49. Knight Therapeutics has a 1 year low of C$4.35 and a 1 year high of C$5.95. The company has a debt-to-equity ratio of 9.25, a quick ratio of 1.79 and a current ratio of 3.20.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). The firm had revenue of C$74.20 million for the quarter, compared to analysts’ expectations of C$78.37 million. Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. Analysts predict that Knight Therapeutics will post 0.0202158 earnings per share for the current year.

Insider Buying and Selling at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan acquired 6,200 shares of the stock in a transaction on Monday, April 1st. The shares were bought at an average price of C$5.25 per share, with a total value of C$32,550.00. 46.45% of the stock is owned by corporate insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.